Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | June 10, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 7,579 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Sale · Disposed 2,412 · Balance 7,579 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | SaleCommon Stock, par value $0.0001 per share | 2,412 | $7.91 | $19,087.84 |
DisclosureSEC source: 0001193125-26-267655 · ownership.xml · nonDerivative · entry 1 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,579 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:05 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 12,300 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001193125-26-234851 · ownership.xml · derivative · entry 2 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2026-05-19 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:05 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234851 · ownership.xml · nonDerivative · entry 1 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,991 F1 · shares: On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 20:54 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionStock options (right to buy) · Derivative | 1,060 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001193125-25-245262 · ownership.xml · derivative · entry 3 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,247 Underlying: Common Stock · 1,060 shares Expires 2032-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 20:54 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | SaleCommon Stock, par value $0.0001 per share | 1,060 | $20.50 | $21,730.00 |
DisclosureSEC source: 0001193125-25-245262 · ownership.xml · nonDerivative · entry 2 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,191 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024. F1 · balance_after: This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 20:54 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionCommon Stock, par value $0.0001 per share | 1,060 | $4.80 | $5,088.00 |
DisclosureSEC source: 0001193125-25-245262 · ownership.xml · nonDerivative · entry 1 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 16,000 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0000950170-25-080310 · ownership.xml · derivative · entry 3 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-30 F5 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080310 · ownership.xml · nonDerivative · entry 2 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,191 F3 · shares: On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F4 · balance_after: This amount includes 4,800 unvested RSUs that were granted on May 30, 2025. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | SaleCommon Stock, par value $0.0001 per share | 1,392 | $7.25 | $10,095.62 |
DisclosureSEC source: 0000950170-25-080310 · ownership.xml · nonDerivative · entry 1 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,391 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.16 to $7.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:26 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068005 · ownership.xml · nonDerivative · entry 1 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F1 · balance_after: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:53 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 2,783 | $0.00 Strike: $45.92 | $0.00 |
DisclosureSEC source: 0001209191-24-005670 · doc4.xml · derivative · entry 1 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 Underlying: Common Stock · 2,783 shares Expires 2034-05-16 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:33 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001209191-23-031474 · doc4.xml · derivative · entry 1 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2033-05-18 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 13:38 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 159,200 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001209191-22-051425 · doc4.xml · derivative · entry 1 Altmeyer Anne · CIK 0001947086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,200 Underlying: Common Stock · 159,200 shares Expires 2022-09-26 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.